Bafna Pharmaceuticals has received renewal certificate, from UK Medicines and Healthcare products Regulatory Agency (MHRA).
The company’s facility, following the audit conducted has got renewal approval as per the guidelines of European Good Manufacturing Practices (EUGMP). Further, the board of directors of the company are scheduled to meet on May 28 to consider the unaudited financial results, for the quarter and the year ended March 31, 2018.
No comments:
Post a Comment